Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors

Detalhes bibliográficos
Autor(a) principal: Pezzini, Marina Ferri
Data de Publicação: 2020
Outros Autores: Cheinquer, Hugo, Araujo, Alexandre de, Cerski, Carlos Thadeu Schmidt, Sprinz, Eduardo, Wolff, Fernando Herz, Poeta, Julia
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/230474
Resumo: Chronic liver disease is an important cause of morbidity and mortality among people living with human immunodefciency virus (HIV) and is frequently related to non-alcoholic fatty liver disease (NAFLD). The objective is to estimate the prevalence and risk factors of hepatic steatosis among consecutive patients with stable HIV infection on antiretroviral therapy (ART). Also, the use of transient elastography (TE) as a mean to identify a subgroup at risk for non-alcoholic steatohepatitis (NASH) and/or liver fbrosis. HIV infected patients were enrolled between August2016 and February2017. Inclusion criteria: ≥18 years with undetectable HIV viral load. Exclusion criteria: pregnancy; alcohol intake ≥20g/day and co-infection B or C viruses. Patients underwent ultrasound (US) to diagnose liver steatosis. Signifcant fbrosis (≥F2) was estimated if at least one of the following were present: APRI>1.0, FIB4>3 and/ or liver stifness ≥7.1kPa. Subjects with TE≥7.1kPa were proposed a liver biopsy and NAFLD Scoring System (NAS)≥3 was considered as diagnosis of NASH. A total of 98 patients were included. Liver steatosis was diagnosed in 31 patients (31.6%) and was independently associated with male gender, BMI, ALT and total bilirubin levels. The prevalence of signifcant fbrosis assessed by TE, APRI and FIB4 was 26.9%, 6.4% and 3.2%, respectively. Seven patients had a TE result ≥7.1kPa. NASH was found in 5 (83.3%). Among HIV infected patients undergoing ART, almost one third have NAFLD. Neither TE, APRI or FIB4 were able to act as surrogates for signifcant liver fbrosis. Nevertheless, TE≥7.1kPa was able to accurately select a subgroup of patients at risk for NASH.
id UFRGS-2_6781ca7d059816e8eb9f157a6eef4a1e
oai_identifier_str oai:www.lume.ufrgs.br:10183/230474
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Pezzini, Marina FerriCheinquer, HugoAraujo, Alexandre deCerski, Carlos Thadeu SchmidtSprinz, EduardoWolff, Fernando HerzPoeta, Julia2021-10-05T04:26:36Z20202045-2322http://hdl.handle.net/10183/230474001131196Chronic liver disease is an important cause of morbidity and mortality among people living with human immunodefciency virus (HIV) and is frequently related to non-alcoholic fatty liver disease (NAFLD). The objective is to estimate the prevalence and risk factors of hepatic steatosis among consecutive patients with stable HIV infection on antiretroviral therapy (ART). Also, the use of transient elastography (TE) as a mean to identify a subgroup at risk for non-alcoholic steatohepatitis (NASH) and/or liver fbrosis. HIV infected patients were enrolled between August2016 and February2017. Inclusion criteria: ≥18 years with undetectable HIV viral load. Exclusion criteria: pregnancy; alcohol intake ≥20g/day and co-infection B or C viruses. Patients underwent ultrasound (US) to diagnose liver steatosis. Signifcant fbrosis (≥F2) was estimated if at least one of the following were present: APRI>1.0, FIB4>3 and/ or liver stifness ≥7.1kPa. Subjects with TE≥7.1kPa were proposed a liver biopsy and NAFLD Scoring System (NAS)≥3 was considered as diagnosis of NASH. A total of 98 patients were included. Liver steatosis was diagnosed in 31 patients (31.6%) and was independently associated with male gender, BMI, ALT and total bilirubin levels. The prevalence of signifcant fbrosis assessed by TE, APRI and FIB4 was 26.9%, 6.4% and 3.2%, respectively. Seven patients had a TE result ≥7.1kPa. NASH was found in 5 (83.3%). Among HIV infected patients undergoing ART, almost one third have NAFLD. Neither TE, APRI or FIB4 were able to act as surrogates for signifcant liver fbrosis. Nevertheless, TE≥7.1kPa was able to accurately select a subgroup of patients at risk for NASH.application/pdfengScientific reports. London. Vol. 10 (2020), 8282, 6 p.HIVFigado gordurosoPrevalênciaFatores de riscoBrasilHepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factorsEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001131196.pdf.txt001131196.pdf.txtExtracted Texttext/plain30140http://www.lume.ufrgs.br/bitstream/10183/230474/2/001131196.pdf.txt95856f3df845dd735c238690e39e8585MD52ORIGINAL001131196.pdfTexto completo (inglês)application/pdf1107129http://www.lume.ufrgs.br/bitstream/10183/230474/1/001131196.pdfc61847d3b9b4fe70eefcc49d0dd7f7d7MD5110183/2304742021-11-20 06:05:03.727324oai:www.lume.ufrgs.br:10183/230474Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2021-11-20T08:05:03Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors
title Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors
spellingShingle Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors
Pezzini, Marina Ferri
HIV
Figado gorduroso
Prevalência
Fatores de risco
Brasil
title_short Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors
title_full Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors
title_fullStr Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors
title_full_unstemmed Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors
title_sort Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors
author Pezzini, Marina Ferri
author_facet Pezzini, Marina Ferri
Cheinquer, Hugo
Araujo, Alexandre de
Cerski, Carlos Thadeu Schmidt
Sprinz, Eduardo
Wolff, Fernando Herz
Poeta, Julia
author_role author
author2 Cheinquer, Hugo
Araujo, Alexandre de
Cerski, Carlos Thadeu Schmidt
Sprinz, Eduardo
Wolff, Fernando Herz
Poeta, Julia
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Pezzini, Marina Ferri
Cheinquer, Hugo
Araujo, Alexandre de
Cerski, Carlos Thadeu Schmidt
Sprinz, Eduardo
Wolff, Fernando Herz
Poeta, Julia
dc.subject.por.fl_str_mv HIV
Figado gorduroso
Prevalência
Fatores de risco
Brasil
topic HIV
Figado gorduroso
Prevalência
Fatores de risco
Brasil
description Chronic liver disease is an important cause of morbidity and mortality among people living with human immunodefciency virus (HIV) and is frequently related to non-alcoholic fatty liver disease (NAFLD). The objective is to estimate the prevalence and risk factors of hepatic steatosis among consecutive patients with stable HIV infection on antiretroviral therapy (ART). Also, the use of transient elastography (TE) as a mean to identify a subgroup at risk for non-alcoholic steatohepatitis (NASH) and/or liver fbrosis. HIV infected patients were enrolled between August2016 and February2017. Inclusion criteria: ≥18 years with undetectable HIV viral load. Exclusion criteria: pregnancy; alcohol intake ≥20g/day and co-infection B or C viruses. Patients underwent ultrasound (US) to diagnose liver steatosis. Signifcant fbrosis (≥F2) was estimated if at least one of the following were present: APRI>1.0, FIB4>3 and/ or liver stifness ≥7.1kPa. Subjects with TE≥7.1kPa were proposed a liver biopsy and NAFLD Scoring System (NAS)≥3 was considered as diagnosis of NASH. A total of 98 patients were included. Liver steatosis was diagnosed in 31 patients (31.6%) and was independently associated with male gender, BMI, ALT and total bilirubin levels. The prevalence of signifcant fbrosis assessed by TE, APRI and FIB4 was 26.9%, 6.4% and 3.2%, respectively. Seven patients had a TE result ≥7.1kPa. NASH was found in 5 (83.3%). Among HIV infected patients undergoing ART, almost one third have NAFLD. Neither TE, APRI or FIB4 were able to act as surrogates for signifcant liver fbrosis. Nevertheless, TE≥7.1kPa was able to accurately select a subgroup of patients at risk for NASH.
publishDate 2020
dc.date.issued.fl_str_mv 2020
dc.date.accessioned.fl_str_mv 2021-10-05T04:26:36Z
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/230474
dc.identifier.issn.pt_BR.fl_str_mv 2045-2322
dc.identifier.nrb.pt_BR.fl_str_mv 001131196
identifier_str_mv 2045-2322
001131196
url http://hdl.handle.net/10183/230474
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Scientific reports. London. Vol. 10 (2020), 8282, 6 p.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/230474/2/001131196.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/230474/1/001131196.pdf
bitstream.checksum.fl_str_mv 95856f3df845dd735c238690e39e8585
c61847d3b9b4fe70eefcc49d0dd7f7d7
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1801225038259552256